The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
The UK has found six confirmed cases of the Brazilian COVID mutation yesterday (28 February) - but an individual who tested positive three weeks ago is still being traced throughout the country.
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
The Government unveiled the confirmed priority groups for phase two of UK vaccinations - the Joint Committee on Vaccination and Immunisation (JCVI) is choosing age as the deciding factor.
Germans have only taken 270,986 AstraZeneca doses so far, leaving roughly 1.17 million doses in storage across the country - but these shots are due to expire in less than six months.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, explains how the COVID-19 pandemic is the scenario for testing and demonstrating the successful implementation of diabetes telehealth platforms.
New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
The research team believe that some people have a genetic predisposition that increases likelihood of severe COVID, which may be crucial to understanding how mutations could change outcomes.
Research found that the supported housing and integrated mental health system could save the NHS £950 million if used as a national strategy for social care.
A new report published in The Lancet investigates why 43% of HIV deaths in 2018 happened in the Black community, with policy solutions for the ongoing HIV epidemic.
The Sinovac COVID vaccine was revealed to be working at 50.4% efficacy by the Butantan Institute last month, but new data suggests that this could actually be 62%.
COVID brought the idea of mRNA vaccines to the attention of the world - now, cancer researchers are investigating how a similar vaccine could stop tumours in a single treatment.
The Pfizer and BioNTech vaccine appears to be significantly less efficient against the South African mutation, but can still stop hosts from experiencing severe COVID and dying from the virus.
New data from the REACT study finds that the number of COVID cases in hospitals is higher than it was in April 2020, but that infection rates are substantially decreasing across the country.
The European Commission today (17 February) launched the "HERA Incubator", as both a "blueprint" for long-term health emergencies and a way to stop COVID-19 mutations.
